Cycle Pharmaceuticals and Handa Therapeutics Sign Sales Agreement for FDA-Approved Leukemia Drug PHYRAGO

Cycle and Handa Signed an Exclusive Sales License Agreement

Announcement

Cycle Pharmaceuticals signed a us commercialization (sales) agreement with Handa Therapeutics LLC for PHYRAGO distribution (availability). The PHYRAGO is an FDA-approved drug for the treatment of the two types of leukemia, Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). PHYRAGO is a pharma’s first oncology product, and ninth commercial product, and will witness the company’s expansion into the expertise in patients’ care suffering from chronic conditions into oncology. This license agreement will help both the company’s to expand and develop in their respective area and promote the product strategically.

About PHYRAGO

PHYRAGO is a narrative formulation of Sprycel (dasatinib) that enables concomitant use with proton pump inhibitors (PPIs) and H2 receptor antagonists (h2ras). This formulation is beneficial for patients on dasatinib therapy, which is prescribed with both medications. With the help of Sprycel, the drug’s visibility of dasatinib can be prominently decreased by 40% more and 60% when operated with H2Ras and PPIs, respectively.

In variation with PHYRAGO, there’s no clinical reduction in the bioavailability of dasatinib that was identified following the concomitant use with H2Ras or PPIs. The warnings for fluid retention, myelosuppression, bleeding events, cardiovascular toxicity, QT prolongation, tumor lysis syndrome, severe dermatologic reactions, pulmonary arterial hypertension, embryo-fetal toxicity, and other effects on growth and development in pediatric patients are covered under the testing and trials.

Further, PHYRAGO, a kinase inhibitor, includes warnings and precautions under different circumstances and cases. Drug interactions, according to the doses for various situations such as lactation, pregnancy, pediatric use, and geriatric use, are mentioned in detail at www.phyrago.com/PI/.

Handa will be working with Cycle Pharma to introduce PHYRAGO officially in September 2025. Phyrago will be introduced with the class patient support from Cycle Vita, serving individualized educational, financial, and product assistance to adult patients with Ph+ALL and Ph+CML.

Views and Statements

President and ceo of Handa Therapeutics, LLC, Bill Liu said, “We are thrilled for our second partnership with Cycle and the expansion of our patient support and care to oncology. Along with PHYRAGO cycle vitas’ expertise in delivering individualized care to patients, it will soon be accessible to leukemia patients. We are proud of this collaboration with Cycle Pharmaceuticals in the marketing of PHYRAGO, the first-ever dasatinib product that can be considered concomitantly with H2Ras and PPIs. Our company is committed to discovering quality oncology treatments like PHYRAGO for patients.”